OTCMKTS:BICX Biocorrx Q1 2026 Earnings Report $0.21 +0.01 (+5.47%) As of 10:02 AM Eastern ProfileEarnings History Biocorrx EPS ResultsActual EPS-$0.03Consensus EPS -$0.06Beat/MissBeat by +$0.03One Year Ago EPSN/ABiocorrx Revenue ResultsActual Revenue$0.22 millionExpected Revenue$0.22 millionBeat/MissMissed by -$5.00 thousandYoY Revenue GrowthN/ABiocorrx Announcement DetailsQuarterQ1 2026Date5/15/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsBiocorrx's next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Biocorrx Earnings HeadlinesBiocorrx Inc. (OTCMKTS:BICX) Stock Short Interest Drops 44.3%September 30 at 2:41 AM | americanbankingnews.comBioCorRx Inc. Appoints Former Acting White House Drug Policy Director Richard J. Baum to Strategic Advisory BoardSeptember 10, 2026 | finance.yahoo.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 1 at 1:00 AM | Chaikin Analytics (Ad)BioCorRx Announces National Drug Codes (NDCs) for LUCEMYRA (lofexidine) Brand and Authorized Generic (AG) SKUs to Ensure Uninterrupted Market SupplyAugust 25, 2026 | finance.yahoo.comBioCorRx Inc.April 21, 2026 | marketwatch.comBioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant TechnologyMarch 11, 2026 | finance.yahoo.comSee More Biocorrx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email. Email Address About BiocorrxBiocorrx (OTCMKTS:BICX) develops addiction treatment programs and related products designed to support individuals seeking recovery from alcohol and substance use disorders. The company’s offerings include the BioCorRx Recovery Program, which combines an initial detoxification protocol with counseling, behavioral support and ongoing recovery services. BioCorRx describes the program as non-addictive and designed to be delivered through qualified treatment providers. The company also develops and markets nutritional supplements intended to support recovery and help address cravings and related wellness needs. Its product portfolio has included the UnBuzzed line and other supplements associated with alcohol-recovery support. BioCorRx licenses its recovery program and related intellectual property to independent providers, allowing treatment centers and practitioners to offer the program under the BioCorRx model. BioCorRx serves customers primarily through a network of licensed treatment providers and healthcare professionals in the United States. The company is headquartered in California. Lourdes Felix has served as BioCorRx’s chief executive officer and has been associated with the company’s development and expansion of its addiction-recovery programs.View Biocorrx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
